A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

NCT07285967 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety
Tolerability
Pharmacokinetics

Interventions

DRUG: Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
DRUG: Placebo

Sponsor

Hangzhou Yirui Pharmaceutical Technology Co., Ltd